02.08.23 -- Exploring Formulation, Tech Transfer, And Delivery For Biologics

Executives from Moderna, Sanofi Pasteur, Takeda, and Catalent shared behind-the-scenes information on their respective efforts to develop a COVID-19 vaccine. With different approaches, the companies all adopted a collaborative mindset to arrive at a vaccine as quickly and safely as possible.

Review key considerations for formulation screening of therapeutic proteins and how consistency, planning, and communication are essential for a successful biologic drug product tech transfer.

While traditional fed-batch bioreactor process development has been well defined, there is a desire to intensify the fed-batch process strategy to increase efficiency and productivity. Discover how to combine N-1 perfusion with the ambr®15 bioreactor system to create a powerful tool for rapid development of a highly efficient cell culture process.

Excipients are valuable substances used to improve stability and potency, but their sourcing and stability can be a challenge. A two-method solution to evaluate one such excipient, PS-80, for quantity and quality has multiple applications for drug developers looking to utilize this in their final product.